Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D005813:Genes, Synthetic; D005822:Genetic Vectors; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D015994:Incidence; D007223:Infant; D007258:Informed Consent; D007376:Interleukin-2 / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009447:Neuroblastoma / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D012190:Retroviridae / Q000235:genetics; D012449:Safety; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured / Q000637:transplantation*; D014481:United States / Q000453:epidemiology
D007155:Immunologic Factors; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins